Skip to main content
. Author manuscript; available in PMC: 2022 May 17.
Published in final edited form as: Small. 2022 Apr 7;18(19):e2200125. doi: 10.1002/smll.202200125

Figure 5.

Figure 5.

Decoy vesicles are robust to drug-resistant Spike mutations. A) Cartoon depicting the SARS-CoV-2 Spike variants investigated in this study and their relative susceptibility to inhibition by soluble ACE2 (sACE2) or monoclonal antibody (mAb) treatments. B) Top: Dose-response curves depicting the inhibition of various strains of SARS-CoV-2 Spike pseudotyped lentivirus (Spike-lenti) against soluble ACE2, WT-ACE2 UC-EVs, and Mut-ACE2 UC-EVs. Curves are normalized to the percent of cells transduced at the lowest EV dose in a particular curve. Symbols repesent the mean of three biological replicates; error bars are standard error of the mean. Data are representative of two independent experiments. B) Bottom: Log(ID50) values calculated from the data in the top portion of this panel. Numbers above each point report the relative resistance for a given strain relative to the parental (D614G) strain for that particular inhibitor treatment. Error bars represent 95% confidence intervals for the parameter (ID50) estimation.